31st December 2021 – Global Antifungal Drugs Market is anticipated to reach USD 12.6 billion by 2025. Anti-fungal drugs, as the name suggests, are used to cure fungal infections. Common fungal infections such as ringworm, fungal nail infection, and vaginal infection typically occur on the external surface of the body, although specific fungal invasive infections occur in some internal body organs such as brain and lungs. The factors that propel the growth of the Antifungal Drugs Market include increasing occurrence of fungal infections across the globe, increasing consciousness, and ongoing research and development in anti-fungal drugs. On the other hand, there are factors that may hamper the growth of the market including occurrence of counterfeit drugs and resistance towards antifungal drugs.
The antifungal agents presently available for the treatment of complete fungal infections are: amphotericin B and lipid formulations of amphotericin B, azoles,5-fluorocytosine, ketoconazole, miconazole, fluconazole and itraconazole. Antifungal Drugs Industry is anticipated to grow at a significant CAGR in the upcoming period as the scope, product types, and its applications are increasing across the globe. The industry may be explored by drug type, dosage form, infection type, therapeutic indications and geography.
Access Antifungal Drugs Market Report with TOC @ https://www.millioninsights.com/industry-reports/antifungal-drugs-market
Antifungal Drugs Market may be explored by drug type as Azoles may further include (Thiazoles, Voricanazole, Imidazole's, and Others), Echinocandins may further include (Anidulafungin, Micafungin, Caspofungin, and Others), Allylamines may further include (Naftifine, Terbinafine, Butenafine, and Others), and Polyenes may further include (Amphotericin B, Candicidin, Natamycin, Hamycin, and Others). The "Azoles" segment led the Antifungal Drugs Industry in 2015 and is anticipated to maintain its dominance by 2025. The key factor that could be attributed to the growth may include composition of important agents such as Vfend, Diflucan, and Noxafil, and extensive usage in the treatment of candidemia, blastomycosis, systemic candidiasis and ocular fungal infections.
The dosage form that could be explored in the Antifungal Drugs Industry include Drugs, Ointments, Powders, and Others. The industry could be explored based on infection type as Systemic Antifungal Infections, and superficial Antifungal Infections. The market may be analyzed by therapeutic indications as Dermatophytosis, Aspergillosis, Candidiasis, and Others. The "Dermatophytosis" segment led the market in 2015 and is anticipated to maintain its dominance by 2025. The factors that could be attributed to the growth include increasing occurrence of skin infections in kids, and rise in the incidence of opportunistic fungal infections that will eventually surge the Dermatophytosis segment in the forecast period.
North America accounted for the major share of the Antifungal Drugs Market Size in 2015 and will continue to lead in the forecast period. The factors that could be attributed to the growth include high patient consciousness levels, and R&D strength pertaining to new drug development.
Some of the key players that fuel the growth of the Antifungal Drugs Industry comprise Sigma-Aldrich Corporation, Astellas Pharma, Inc., Agilent Technologies, Inc., Inc. (a subsidiary of Danaher Corporation), Beckman Coulter, Kramer Laboratories, Valeant Pharmaceuticals International, Inc., Tecan Group, and Basilea Pharmaceutical Ltd. The leading companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost the inorganic growth of the industry.
Request a Sample Copy of Antifungal Drugs Market Report @ https://www.millioninsights.com/industry-reports/antifungal-drugs-market/request-sample
WordPress.com
No comments:
Post a Comment